Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroepithelial Tumor Clear all
Withdrawn Phase 1 Interventional

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

NCT01130623
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

D2C7 for Adult Patients With Recurrent Malignant Glioma

NCT02303678
View directory record Official record
Conditions
Malignant Glioma, Brain Tumor, Recurrent
Interventions
D2C7-IT
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Results available

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017
View directory record Official record
Conditions
Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions
Cabiralizumab, Nivolumab
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
39
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting No phase listed Observational

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

NCT00588068
View directory record Official record
Conditions
Neuroblastoma
Interventions
Tumor and Marrow Markers
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
2,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma

NCT00058123
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
poly ICLC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 1Phase 2 Interventional

TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma

NCT00074334
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
TGFa-PE38 immunotoxin, conventional surgery
Biological · Procedure
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2009 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

NCT02202993
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM)
Interventions
Mibefradil with Radiation
Drug
Lead sponsor
Cavion, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Not yet recruiting Phase 2 Interventional

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma

NCT07735819
View directory record Official record
Conditions
Low Grade Glioma, Glioblastoma
Interventions
Minocycline 200mg/day, [18F]FETrp PET/CT
Drug · Diagnostic Test
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT03566199
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Panobinostat Nanoparticle Formulation MTX110, Convection-Enhanced Delivery (CED)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

NCT01598597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

NCT03426891
View directory record Official record
Conditions
Glioblastoma, Brain Tumor, GBM
Interventions
Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00068510
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Recruiting Early Phase 1 Interventional

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

NCT05632562
View directory record Official record
Conditions
High Grade Glioma
Interventions
O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

NCT00002572
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes, conventional surgery
Biological · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
3
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Suspended Phase 1Phase 2 Interventional

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

NCT06639607
View directory record Official record
Conditions
Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
Interventions
PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 25 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2051
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma

NCT01020292
View directory record Official record
Conditions
Glioma
Interventions
Nelfinavir
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting Phase 1 Interventional

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

NCT05236036
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy, Temozolomide
Drug · Other · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Results available

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

NCT01059071
View directory record Official record
Conditions
Neuroblastoma
Interventions
DFMO, Etoposide
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

NCT00509431
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Erlotinib + Sirolimus
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 1 Interventional

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

NCT00826930
View directory record Official record
Conditions
High Grade Glioma
Interventions
Trans Sodium Crocetinate (TSC)
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Not applicable Interventional

Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT

NCT04763031
View directory record Official record
Conditions
Glioblastoma, GBM, Recurrent GBM
Interventions
Intra-operative Radiation Therapy - IORT
Radiation
Lead sponsor
Parkridge Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 28, 2026, 4:52 AM EDT